#1 Clinical Trials Search in Europe

Anti-Sars-Cov-2 Polyclonal Hyperimmune Globulin

This article discusses a clinical trial investigating the use of Anti-SARS-CoV-2 Polyclonal Hyperimmune Globulin, also known as hyperimmune intravenous immunoglobulin (hIVIG), for treating adults with early symptoms of COVID-19. The study aims to assess the safety and effectiveness of this treatment compared to a placebo in outpatient settings, focusing on improving clinical status within seven days of administration.

Table of Contents

What is Anti-SARS-CoV-2 Polyclonal Hyperimmune Globulin?

Anti-SARS-CoV-2 Polyclonal Hyperimmune Globulin is a potential treatment for COVID-19 that is currently being studied in clinical trials. It is also known by several other names, including COVID-HIGIV, Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human), and COVID-19 hIVIG.[1]

This treatment is a type of passive immunotherapy, which means it provides ready-made antibodies to help fight the SARS-CoV-2 virus, rather than stimulating the body to produce its own antibodies (as vaccines do).[1]

How Does It Work?

The treatment contains antibodies that have been collected from the blood of people who have recovered from COVID-19. These antibodies are concentrated and purified to create a solution that can be given to patients with early COVID-19 symptoms. The idea is that these antibodies will help the patient’s immune system fight off the virus more effectively, potentially reducing the severity of the illness and preventing complications.[1]

Clinical Trial Information

A large international clinical trial is being conducted to evaluate the safety and effectiveness of this treatment. The trial is called “Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC)”. It is a randomized, double-blind, placebo-controlled trial, which means that participants are randomly assigned to receive either the actual treatment or a placebo, and neither the participants nor the researchers know who is receiving which.[1]

Who Can Participate in the Trial?

The trial is looking for participants who meet certain criteria. These include:

  • Adults aged 55 or older, or adults (18 or older) with an immunosuppressed condition
  • Recently tested positive for SARS-CoV-2 (within 5 days)
  • Experiencing symptoms of COVID-19 for 5 days or less
  • Not currently hospitalized or being evaluated for hospitalization

There are also several conditions that would exclude someone from participating, such as certain blood disorders, a history of severe allergic reactions to blood products, or known IgA deficiency.[1]

How is the Treatment Administered?

The treatment is given as a single intravenous infusion. This means it’s delivered directly into the bloodstream through a vein. The infusion contains either the active treatment (hyperimmune globulin) or a placebo, depending on which group the participant is assigned to. The infusion takes place on the day the participant joins the study.[1]

How Will Effectiveness be Measured?

The researchers will evaluate the effectiveness of the treatment in several ways, including:

  • Assessing the participants’ clinical status after 7 days
  • Monitoring for hospitalization or death over 28 days
  • Measuring changes in the amount of virus in the body
  • Evaluating the severity of respiratory symptoms
  • Tracking how quickly participants return to their pre-COVID health status

These measurements will help determine whether the treatment is effective in reducing the severity of COVID-19 and speeding up recovery.[1]

Safety Considerations

As with any medical treatment, safety is a key concern. The trial excludes people with certain conditions that might put them at higher risk of complications. These include:

  • Recent history of blood clots or certain blood clotting disorders
  • Known allergies to blood products or components of the treatment
  • Certain heart conditions that might make it risky to receive the amount of fluid in the infusion

The researchers will closely monitor all participants for any side effects or adverse reactions throughout the study.[1]

Aspect Details
Study Title Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC)
Main Objective Compare safety and efficacy of hIVIG vs placebo in outpatients with recently diagnosed SARS-CoV-2 infection
Treatment Single infusion of 50-300 mL of Anti-COVID-19 Hyperimmune Globulin (Human) or placebo
Primary Endpoint Clinical status after seven days on a 5-point ordinal scale
Key Inclusion Criteria Age ≥55 or ≥18 with immunosuppression, positive SARS-CoV-2 test within 5 days, ≤5 days from symptom onset
Key Exclusion Criteria Asymptomatic, pneumonia, hypoxia, recent thrombotic conditions, IgA deficiency
Follow-up Duration 28 days
Secondary Outcomes Hospitalization, mortality, disease progression, viral burden, antibody levels, healthcare resource utilization

FAQ

  • What is Anti-SARS-CoV-2 Polyclonal Hyperimmune Globulin? Anti-SARS-CoV-2 Polyclonal Hyperimmune Globulin is a type of passive immunotherapy that contains antibodies against the SARS-CoV-2 virus. It is given as an intravenous infusion to help fight the virus in people with early COVID-19 symptoms.
  • Who is eligible for this clinical trial? The trial is open to adults aged 55 and older, or those 18 and older with an immunosuppressed condition. Participants must have a positive SARS-CoV-2 test within 5 days and be within 5 days of symptom onset.
  • How is the treatment administered? The treatment is given as a single intravenous infusion of 50 to 300 mL on the day of randomization (day 0). Participants receive either the active treatment or a placebo.
  • What are the main outcomes being measured? The primary outcome is the participant's clinical status after seven days, measured on a 5-point scale ranging from asymptomatic with no limitations to critical illness or death. Secondary outcomes include hospitalization rates, mortality, and disease progression.
  • How long does the study follow participants? The study follows participants for 28 days after receiving the treatment, monitoring various aspects of their health status and COVID-19 progression during this period.

Ongoing Clinical Trials on Anti-Sars-Cov-2 Polyclonal Hyperimmune Globulin

  • Study on Anti-COVID-19 Hyperimmune Globulin for Treating Adults with Early COVID-19 Symptoms

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Denmark Greece Spain

Glossary

  • Hyperimmune Intravenous Immunoglobulin (hIVIG): A concentrated solution of antibodies derived from the plasma of individuals who have recovered from COVID-19, designed to provide immediate immunity against the SARS-CoV-2 virus.
  • Passive Immunotherapy: A type of treatment that involves giving pre-formed antibodies to a person to provide immediate, short-term protection against a specific infection or disease.
  • Ordinal Scale: A measurement scale used in this study to categorize the severity of COVID-19 symptoms and limitations, ranging from asymptomatic to critical illness or death.
  • Standard of Care (SOC): The typical treatment or care given to patients with a specific condition, which serves as a comparison for new treatments being studied.
  • Direct-acting Antiviral (DAA): A type of medication that directly interferes with the ability of a virus to multiply and spread in the body.
  • Nucleic Acid Amplification Test (NAAT): A type of viral diagnostic test for SARS-CoV-2 that detects the virus's genetic material.
  • Hypoxia: A condition in which the body or a part of the body does not receive enough oxygen from the blood.
  • SpO2: Saturation of peripheral oxygen, a measure of how much oxygen the blood is carrying as a percentage of the maximum it could carry.
  • ECMO: Extracorporeal Membrane Oxygenation, a life support machine that takes over the function of the heart and lungs in severe cases of respiratory failure.

References

  1. http://clinicaltrials.eu/trial/study-on-anti-covid-19-hyperimmune-globulin-for-treating-adults-with-early-covid-19-symptoms/